About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Zyrtec and Claritin's New Eye Drops Contain Neither Zyrtec Nor Claritin

By Jim Edwards | Aug 19, 2009

There’s a strange war brewing between Johnson & Johnson’s McNeil Consumer Healthcare unit and Schering-Plough over their monster allergy brands Zyrtec and Claritin.

Both companies have extended their brands into new eye-drops products, but despite carrying the Zyrtec and Claritin names neither eye-drops brand contains any of the drugs that consumers know as Zyrtec or Claritin.

The drug in Schering’s Claritin pills is loratadine, but Claritin Eye contains ketotifen, not loratadine. The drug in McNeil’s Zyrtec pills is cetirizine, but Zyrtec Itchy Eye Drops contains ketotifen fumarate, not cetirizine. A note on the Zyrtec web site says:

The ingredients and uses of this product are different than other ZYRTEC products.

The Claritin web site only distinguishes the products when you click to look at the ingredients label.

Messages left for McNeil and Schering were not immediately returned. The obvious question: Was it a good idea for the FDA to approve two different drugs under the same name?

Disclosure: The author is a longtime Claritin user.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Big pharma to stop Bolivian dengue fever spread

    Scrip News - 314 days 9 hours 12 minutes ago

    McNeil Consumer Healthcare, Abbott Laboratories and Baxter Healthcare have joined the charity Direct Relief International to help stop the spread of dengue fever in Bolivia. McNeil, a subsidiary of Johnson & Johnson, will provide

  • F.D.A. Allows New Remedy for Arthritis

    New York Times - 290 days 18 hours 44 minutes ago

    The new drug is a follow-up to Remicade, which is marketed in the United States by Johnson & Johnson and in Europe and in other countries by the Schering-Plough Corporation

  • J&J brings arbitrators into Remicade dispute

    FiercePharma - 257 days 8 hours 58 minutes ago

    It's official: Johnson & Johnson has asked official arbiters to let it abandon its Remicade partnership with Schering-Plough. J&J contends that the Merck/Schering merger amounts to a "change in control," which would allow it to terminate the joint distribution deal that covers the blockbuster anti-inflammatory and its new sibling treatment...

  • Johnson & Johnson Expands Recall of Tylenol Arthritis Caplets

    DailyFinance - 42 days 5 hours 17 minutes ago

    The U.S. Food and Drug Administration announced on its MedWatch site Monday that Johnson & Johnson ( JNJ ) is expanding a voluntary recall of Tylenol Arthritis Caplets following consumer reports of nausea and stomach pain. The announcement came 10 days after McNeil Consumer Healthcare, the division of Johnson & Johnson that sells Tylenol...

  • Merck and Schering Q2: Who Needs This Merger More?

    BNET Pharma - 203 days 8 hours 30 minutes ago

    A comparison of Merck and Schering-Plough’s Q2 2009 results shows that both companies’ sales force productivity is flatlining, but that Schering is the weaker partner going into their merger. The basics: Merck sales were down 3 percent to $5.9 billion; net income was down 12 percent to $1.6 billion. Schering’s sales were down 6 percent...

 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

  •  
    1

    EyeDrMike

    08/30/09 | Report as spam

    Ketotifen

    Ketotifen is the generic name for Zaditor, a brand of anti-allergy eyedrops that was first FDA approved in 1999 and went OTC in late 2006. FDA approval was not needed for releases of other brands of the same drug. Use of the Zyrtec and Claritin brand names is simply for name recognition. The irony of this is the fact that Claritin (loratidine) pills have been shown in several studies to be no more effective than placebo, but Ketotifen is actually effective at suppressing histamine release and suppressing the allergy response from circulating histamine. Claritin Eye Drops are more effective than Claritin pills...

    The upside of the proliferation of Ketotifen drops is the fact that, HOPEFULLY, the potentially harmful ocular decongestant eyedrops like Visine, Clear Eyes, Vasocon, Naphcon, Opcon, etc will eventually go away

  •  
    2

    BunnyDog

    10/29/09 | Report as spam

    RE: Zyrtec and Claritin's New Eye Drops Contain Neither Zyrtec Nor Claritin

    I'm glad I read this. I was just getting ready to buy the zyrtec eye drops. I decided to research a little first. Glad I did.

    I agree that Zyrtec IS effective in pill form against Allergies. They completely suppress my symptoms 1 pill = approx 30 hours of no symptoms (for me).

    I have extreme skin reactions to pet dander/dust mites (and I have 3 indoor dogs + 1 cat). The Zyrtec was my daily BEST FRIEND.. but I'm going through IVF and want to stay off pill-form medication until I complete the process. I was hoping to get some relief via the eye drops but now not sure if it will be of much benefit.

    I may try 1 bottle to at least alleviate my itchy eyes. Then proceed if beneficial. But now I'll know not expect it to have a antihistamine effect.

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)